To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated guidance and dementia-specific recommendations: cognitive training may be offered to older adults with normal cognition or mild cognitive impairment and engagement in cognitive stimulation may be encouraged. Engagement in social activity interventions may be recommended. Physical activity should be recommended to adults with normal cognition and may be recommended to adults with mild cognitive impairment. Interventions aimed at reducing or ceasing hazardous and harmful drinking may be offered. Interventions for tobacco cessation should be offered to adults who use tobacco. A healthy, balanced dietary pattern may be recommended, but supplementation of vitamins B and E, omega-3 polyunsaturated fatty acids (PUFA) and multivitamins/minerals is not recommended. Interventions for reducing midlife overweight or obesity may be offered and dietary restriction interventions may be offered to adults who are overweight or obese. Management of diabetes, hypertension, dyslipidaemia at midlife, may be offered. Hearing aids may be offered to adults with hearing loss. Menopausal hormone therapy is not recommended in postmenopausal women aged 65 years and older. Reducing exposure to household and ambient air pollution may reduce the risk or incidence of cognitive decline and/or dementia. Tailored, multidomain interventions may be offered. Source: https://www.who.int/
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…
Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…
In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…
This website uses cookies.